277 results on '"Kieback D"'
Search Results
2. Lokalrezidive nach Mammakarzinom — Auftreten nach subkutaner Mastektomie
3. Der Composition Adjusted Receptor Level (CARL) des Östrogenrezeptors ermöglicht eine individuelle Prognosestellung beim serösen Ovarialkarzinom
4. Mutationen des p53 Tümorsuppressor-Gens beim Mammakarzinom und Suppression des neoplastischen Phänotyps durch Wildtyp p53
5. Adenovirus-Mediated Thymidine Kinase Gene Therapy for Recurrent Ovarian Cancer: Expression of Coxsackie-Adenovirus Receptor and Integrins αvβ3 and αvβ5
6. Aktuelle Studien zur Therapie des Zervixkarzinoms in den USA
7. Correlation of treatment-emergent adverse events and clinical response to endocrine therapy in early breast cancer: a retrospective analysis of the German cohort of TEAM
8. Aktuelle Studien zur Therapie des Zervix- karzinoms in den USA
9. Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12-month, prospective, randomised substudy
10. Aggressive Management of Recurrent Ovarian Cancer - the Challenge of Individualizing Cancer Therapy Illustrated by a Case Report
11. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer
12. Multicenter phase II study of oral capecitabine (Xeloda®) in patients with metastatic breast cancer relapsing after treatment with a taxane-containing therapy
13. Adnexal Masses in Pregnancy
14. Häufige Gen-Polymorphismen beeinflussen das individuelle Mammakarzinom-Risiko von Frauen in Deutschland: V1–4
15. Molecular Mechanisms in Signal Transduction: New Targets for the Therapy of Gynecologic Malignancies
16. Die chemische Heteroduplexspaltung — Ein Verfahren zur Entdeckung von Mutationen in Östrogen- und Progesteronrezeptorgenen beim Mammakarzinom
17. Topotecan Chemotherapy in Patients with Breast Cancer and Brain Metastases: Results of a Pilot Study
18. Problematik der genetischen Information über das Krebsrisiko - die Sicht des Klinikers: 4.1.3 | 1
19. p53-Gen-Chemotherapie bei Ovarialkarzinom: 2.2.2 | 6
20. Rezidivtherapie des Zervixkarzinoms: 2.2.2 | 4
21. Minimal invasive Therapie von Mammatumoren: 2.2.2 | 1
22. Numerical Chromosomal Aberrations in Borderline, Benign, and Malignant Epithelial Tumors of the Ovary: Correlation With p53 Protein Overexpression and Ki-67
23. p53-based blood test for p53PIN3 and risk for sporadic ovarian cancer
24. Abstract P2-09-17: Evaluation of the oncomine comprehensive assay for the identification of actionable mutations for therapeutic stratification from the TEAM pathology cohort
25. The influence of premature rupture of membranes (PROM) on the course of labor
26. Instrumental vaginal delivery today: forceps delivery versus vacuum extraction
27. Häufigkeit und Ursache mammasonographischer Fehldiagnosen
28. Die sonographische Früherkennung des Mammakarzinoms
29. Die Bedeutung ausgewählter seltener Befunde für die mammasonographische Differentialdiagnose
30. The Use of Fetal Surveillance During Labor in the Federal Republic of Germany
31. Defining a signature of residual risk following endocrine treatment in the tamoxifen and exemestane adjuvant multinational (TEAM) trial
32. Das 'Mikrokarzinom' der Mamma — ein sinnvoller Begriff?
33. Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial
34. PIK3CA mutations are linked to PgR expression: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) pathology study
35. A Comparison between AQUA Quantitative Fluorescent Immunohistochemistry and Conventional Immunohistochemistry for Hormone Receptors
36. Mammostrat (R) as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in Postmenopausal Early Breast Cancer: Preliminary Data of the TEAM Pathology Study
37. Post-cesarean adhesions- Are they a unique entity?
38. Was trägt die Mammasonographie zur Therapieplanung beim Mammakarzinom bei?
39. Das nur sonographisch darstellbare Mammakarzinom — Kriterien der Indikationsstellung zur Mammasonographie
40. Do type 1 receptor tyrosine kinases inform treatment choice? A prospectively planned analysis of the TEAM trial
41. 443 The German Cohort of the TEAM Trial: Does Prior Chemotherapy Affect the Efficacy of Endocrine Therapy?
42. Effects of exemestane and tamoxifen on hormone levels within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) Trial: results of a German substudy
43. Increased progression-free and overall survival in patients with breast cancer with menopausal symptoms or arthralgia/myalgia during adjuvant treatment with exemestane or tamoxifen: Results of the German TEAM trial.
44. Abstract P4-08-02: A Comparison between AQUA Quantitative Fluorescent Immunohistochemistry and Conventional Immunohistochemistry for Hormone Receptors
45. Abstract P3-10-33: Mammostrat® as an Immunohistochemical Multigene Assay for Prediction of Early Relapse Risk in Postmenopausal Early Breast Cancer: Preliminary Data of the TEAM Pathology Study
46. Five Years of Exemestane as Initial Therapy Compared to 5 Years of Tamoxifen Followed by Exemestane: The TEAM Trial, a Prospective, Randomized, Phase III Trial in Postmenopausal Women with Hormone-Sensitive Early Breast Cancer.
47. Preliminary Comparison between AQUA and Centralised ER/PgR Analysis within the TEAM Pathology Study.
48. The TEAM Trial Pathology Study Identifies Potential Prognostic and Predictive Biomarker Models for Postmenopausal Patients Treated with Endocrine Therapy.
49. A prospectively planned pathology study within the TEAM trial confirms that progesterone receptor expression is prognostic but is not predictive for differential response to exemestane versus tamoxifen.
50. Results of the first planned analysis of the TEAM (tamoxifen exemestane adjuvant multinational) prospective randomized phase III trial in hormone sensitive postmenopausal early breast cancer.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.